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Objective. Cervical cancer is the second most common cancer among Brazilian women. High-risk human pap-
illomavirus (hr-HPV) persistence is the primary cause of cervical neoplasia. Early detection of hr-HPV is important
for identifying women at risk for developing cervical lesions. Approximately 85% of new cases of cervical cancer
worldwide and 50% of the total cervical cancer deaths occurred in developing countries. Here, a newmethodology
to support a cervical cancer screening program was evaluated in women from various Brazilian regions.
Methods. Two thousand women aged 18–77 years were enrolled in an opportunistic cervical cancer screen-
ing program andwere randomized into self-vaginal or health professional-guided cervical sampling groups. The
Qiagen careHPV™ testwas performed on all samples. Pap tests were performed on all women using liquid-based
cytology.
Results. Positive hr-HPV resultswere obtained in 12.3% (245/2000) of women; similar rateswere observed in
self- or health professional-collected samples. Eighty-nine percent (1719/2000) of cervical cytologies classiﬁed
as normal were negative to hr-HPV. Among the cytological samples, 36.6% classiﬁed as ASC-US+ were positive
to hr-HPV, 78.8% were LSIL and 75.0% were HSIL.
Conclusions. Self-sampled and health professional-sampled vaginal/cervical specimens did not differ in their
rates of detection of hr-HPV. Therefore, HPVDNA testing in self-sampled vaginal cells is an alternative to primary
screening in low-resource settings.© 2013 Elsevier Inc. All rights reserved.Introduction
Cervical cancer (CC) is a well-known disease worldwide and re-
mains a critical public health issue in developing countries thatestigation (LIM) 15, Faculty of





f-collection for high-risk HPV
13.07.092lack appropriate screening programs. Consequently, 85% of cases
and 50% of deaths due to CC occur in developing countries, particularly
in the poorest regions. Most Brazilian regions have dramatic indexes of
mortality: CC is the second most common cancer among Brazilian
women, with mortality rates estimated to be more than 10,000 deaths
annually and more than 17,000 new cases occurring each year [1,2].
Human papillomavirus (HPV) infections are prevalent worldwide.
Persistent hr-HPV infection is the single main risk factor for the devel-
opment of premalignant and malignant cervical lesions [3]. HPV causes
virtually all cases of cervical cancer [4]. Cervical cancer screeningdetection in Brazilianwomen using the careHPV™ test, Gynecol Oncol
2 A.T. Lorenzi et al. / Gynecologic Oncology xxx (2013) xxx–xxxprograms are tailored to optimize the identiﬁcation of precursor lesions
of cervical cancer, thereby contributing to reduction of the associated
mortality. Cervical cancer develops over a long period of time (approx-
imately 20 years from the initial HPV infection to the onset of invasive
cancer), which allows for preventive actions. [5]. A combination of
HPV testingwith liquid-based cytology screening has been demonstrat-
ed to improve the algorithm to protect women against CC. HPV DNA
testing is considered to be the most efﬁcient tool to screen women at
risk for cervical diseases because of the higher sensitivity in comparison
to the cytology examination [6–8]. This superior sensitivity prevents the
high rates of false-negative results usually associated with cytological
examination. As the cytology demands very qualiﬁed skill and stringent
internal quality control system, HPV test could be an alternative to op-
timize the cervical screening programs in countries or regions where
the cytology test is not feasible to be implemented.
Recently, a newmolecular HPVDNA test (careHPV™)was developed
to detect 14 of the main hr-HPV strains (16, 18, 31, 33, 34, 39, 45, 51, 52,
56, 58, 59, 66 and 68) in low-resource or technically poor settings. The
careHPV™ system does not require electricity or ﬂowing water and pro-
vides results for up to 90 samples in a total of 4 h. The test is portable and
can be performed under suboptimal laboratory conditions and in very
small spaces. Moreover, the test is a user-friendly and reproducible
system that encompasses a few easy steps [9]. In comparison with the
performance of the conventional Pap test, HPV DNA testing is more sen-
sitive, practical and analytically objective [5,10,11]. Despite the lower
positive predictive value of self-sampled HPV DNA testing compared
with cytology, a recent study [12] demonstrated that notable HPV results
improved the detection of CIN2+ in developing countries, particularly in
settings with poor human and technology resources. The sensitivity of
HPV DNA testing is fundamental for womenwith limited access to tradi-
tional screening. We anticipated that this HPV test could be an excellent
option for primary screening in many regions of Brazil. The objective of
this study was compare the careHPV™ test results from self-sampling
and health professional collection specimens.
Methods
Study design
This study was performed between March and December 2012 at
the ambulatory wing of the Cancer Prevention department of Barretos
Cancer Hospital (BCH), Barretos, São Paulo, Brazil. Women were ran-
domized into two groups: vaginal self-sampling vs. cervical health pro-
fessional sampling. Sequentially numbered envelopeswere prepared by
a statistics department member of this institution (BCH) to guarantee
adequate randomization. None of the professionals who implemented
the randomization or done the sample collection knew the content of
the envelops (if the samples were self-sampled or collected by profes-
sionals health) or the results of the other tests. This studywas registered
in Clinical Trials (no. NCT01539668).
Ethics
All women received a patient information sheet explaining the study
and provided written consent. The eligible women were invited and
number registered to participate. Approvals were obtained from the
BCH Research Ethic Committee.
Subjects and specimen collection
The study enrolled 2000 volunteer women in an opportunistic
screening at BCH. Eligiblewomenwere older than 18 years. Participants
were informed about theHPV test, CC, the importance of early detection
and cervical cancer prevention and the study objectives. After signing
the informed consent form, each woman picked up an envelope in thePlease cite this article as: Lorenzi AT, et al, Self-collection for high-risk HPV
(2013), http://dx.doi.org/10.1016/j.ygyno.2013.07.092number sequence that provided information about the study group. If
she was sorted for self-sampling, a well-trained professional instructed
thewomanwith an illustrative cartoon concerning how to take the vag-
inal sample without professional intervention; alternatively, the study
nurse collected a standard cervical sample if the woman was referred
to the professional sampling group.
Sample collection
The ﬁrst sample collected was for hr-HPV diagnosis using the
careHPV™ test. A conical-shaped brush (Qiagen, Gaithersburg, MD,
USA) was used to take the vaginal specimen: the woman inserted
the brush head into the vagina up to 10 cm, rotated it (clockwise)
three times before removal and placed the brush immediately in a
careHPV™ medium tube (QIAGEN, USA), which was delivered to
and capped by the study personnel. The health professional
interviewed the women in both groups to complete a structured
questionnaire with socio-demographic information.
Pap test collection and preparation
A second specimen was collected for cervical cytology by a well-
trained professional using a Rover's cytobrush with a removable brush
head (Rover's, Holland). An endocervical and an ectocervical canal sample
were placed immediately in SurePath® (Becton Dickinson, USA). Speci-
mens were sent to the BCH Pathology Department, Barretos, São Paulo,
Brazil, and then were analyzed and classiﬁed using the BD FocalPoint™
Slide Proﬁler. The specimens were reviewed by a cytotechnician, and al-
tered cases (ASC-US+) were revised by a cytopathologist.
HPV DNA test
HPV DNA analysis was performed at the BCH Oncology Molecular
Center, Barretos, São Paulo, Brazil, using the careHPV™ test, which com-
prises an in vitro nucleic acid hybridization assay with signal ampliﬁca-
tion using microplate chemiluminescence for the qualitative detection
of 14-h HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and
68) in cervical specimens [13].
Womenwere informed by letter about their results if theywere HPV
negative or were recalled to follow up if they were HPV positive.
Women who tested positive for hr-HPV and/or with cytology ASC-H+
were referred for colposcopy and/or biopsy (if necessary).
Statistical analysis
The sample size calculation was based on the principle of an equiva-
lence clinical trial, in which the new intervention and the standard one
are equally effective. The prevalence rate of HPV infectionwas supposed
to be around 10–15% in a low-risk population. Considering an alpha
error of 5%, beta error of 10% and clinical acceptable margin of 5% be-
tween self-sampling and professional sampled groups, the sample size
has been estimated from 756 to 1071 subjects in each arm [14].
Statistical analysis was accomplished using the computer software
IBM® SPSS® Statistics (Statistical Package for Social Sciences) version
20.1 for Windows (IBM Corporation, Route 100, Somers, NY 10589).
Chi-squared (χ2) test was used to compare frequencies among groups.
Student's t-test was used to compare means between groups, and
Fisher's exact test was used when the χ2 test was not sufﬁcient for
group comparison. In all tests, p values less than 0.05 were considered
to be statistically signiﬁcant.
Results
A total of 2000 women aged 18–76 years were tested for hr-HPV
using the careHPV™ test by either self-sampling or sample collection
by a health professional. Two hundred forty-ﬁve specimens (12.3%)detection in Brazilianwomen using the careHPV™ test, Gynecol Oncol
Table 1
Comparison between the careHPV™ test, collection group and the valid socio-demographic women questionnaires.
careHPV™ test Source
Positive p value Self-sampling Health professional p value
Age (years)
18–29 28.2% (66) b0.0001 55.1% (129) 44.9% (105) 0.051
30–39 17.3% (60) 53.6% (186) 46.4% (161)
≥40 8.4% (119) 48.3% (685) 51.7% (734)
Parity
None 23.6% (66) b0.0001 52.5% (147) 47.5% (133) 0.645
1–2 10.9% (113) 49.6% (513) 50.4% (521)
N2 9.5% (64) 49.3% (332) 50.7% (341)
Sexual partners
1 8,5% (98) b0.0001 50.3% (577) 49.7% (571) 0.800
2–3 16.9% (81) 51.3% (245) 48.7 (233)
N3 19.1% (53) 48.7% (135) 51.3% (142)
Tobacco use
Yes 13.4% (31) 0.587 49.8% (115) 50.2% (116) 0.970
No 12.2% (213) 49.9% (874) 50.1% (877)
Contraceptive use
Yes 21.3% (69) b0.0001 50.9% (165) 49.1% (159) 0.708
No 10.6% (175) 49.8% (820) 50.2% (827)
One unsatisfactory molecular test.
3A.T. Lorenzi et al. / Gynecologic Oncology xxx (2013) xxx–xxxtested hr-HPV positive; 96.4% of women who participated in this trial
declared that they have at least one Pap test before the study, and
most reported only one lifetime sexual partner. No differences were ob-
served between the collection groups (self or health professional)
regarding variables such as parity, number of sexual partners, contra-
ceptive and tobacco use (p N 0.05; χ2 test) (Table 1). However, when
we considered the careHPV™ results, differences between the collection
groups were observed concerning the variables. Eleven percent of valid
questionnaires included smokers; among them, 13.4% were positive for
hr-HPV infection. In the non-smoking population, 12.2% were positive
for the molecular hr-HPV test. Regarding contraceptive use, 16.45% of
the participants used contraceptives; among them, 21.3% were positive
for hr-HPV. Among the women who did not use contraceptives, 10.6%
were positive for the molecular hr-HPV test (p b 0.0001; χ2 test). Re-
garding parity and the number of sexual partners, statistically signiﬁ-
cant differences were also found.
A slightly higher frequency of hr-HPV positive results was observed
in the self-sampling group compared with the professionally sampled
group (13.5% (135) versus 11% (110), respectively), but these results
were not statistically signiﬁcant (p = 0.087). Themean agewas slightly
increased in the professional collection group (45.6 years), whereas
that in the self-sampling group was 44.5 years (p = 0.034; Student's
t-test).
Considering the cytological results, 10.5% of the non-relevant alter-
ation (NILM) samples were positive for hr-HPV in the molecular test.Table 2
Cytological results relative to careHPV™ test.
careHPV™ test*
Negative Positive p value
NILM 89.5% (1719) 10.5% (201)
ASC-US+ 63.4% (26) 36.6% (15)
LSIL 21.2% (07) 78.8% (26) b0.0001
HSIL 25.0% (01) 75.0% (03)
Total 87.7% (1753) 12.3% (245)
The statistical test used to evaluate the groups was χ2, considering 0.05 of signiﬁcance.
NILM = negative for intraepithelial lesion or malignancy; ASC-US+ = atypical squamous c
signiﬁcance—cannot exclude high-grade lesion; AGC-US+ = atypical glandular cells of undet
cannot exclude high-grade lesion; LSIL = low-grade squamous intraepithelial lesion; HSIL =
*It was excluded of the statistical data analysis two samples with unsatisfactory results (one ca
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(2013), http://dx.doi.org/10.1016/j.ygyno.2013.07.092In four HSIL cases, three (75%) were hr-HPV positive. Additionally, 26
of 33 LSIL (78.8%) cases were positive for the careHPV™ test. Most
(89.5%; n = 1719) of the women with NILM cytological results tested
negative on the HPV molecular test (Table 2).
Discussion
HPV infection is a highly common sexually transmitted infection
among youngwomen, but it ismostly transitory. Conversely, the persis-
tence of hr-HPV in women older than 40 years is associated with cervi-
cal cancer development. hr-HPV is the main cause of death by cancer
among Brazilian women [5,11]. Currently, molecular HPV testing is in-
dicated for screeningwomenwho are at risk for cervical lesion develop-
ment because of its higher sensitivity, decreased subjectivity and better
reproducibility compared with cytology [8–10]. Self-sampling is an im-
portant tool to test women for HPV infection, particularly in developing
countries or remote areas, where it is possible to send suchwomen kits
with brushes, medium collection supplies and illustrative instructions.
This option is relatively inexpensive and may beneﬁt women who
may not otherwise have access to the health system [15,16]. Indepen-
dent of the HPV test used, generally, self-collected samples have similar
frequencies of HPV DNA to samples collected by a health professional
[17]. Our results endorse this premise because no difference was ob-
served between collection procedures. Because careHPV™ is affordable
and can be used in various settings with various collection samples, weSource*
Self-sampling Health professional p value
49.9% (958) 50.1% (963)
53.7% (22) 46.3% (19)
51.5% (17) 48.5% (16) 0.738
75.0% (03) 25.0% (01)
50.0% (1000) 50.0% (999)
ells of undetermined signiﬁcance; ASC-H+ = atypical squamous cells of undetermined
ermined signiﬁcance; AGC-H+ = atypical glandular cells of undetermined signiﬁcance—
high-grade squamous intraepithelial lesion.
reHPV™ test and one liquid-based cytology).
detection in Brazilianwomen using the careHPV™ test, Gynecol Oncol
4 A.T. Lorenzi et al. / Gynecologic Oncology xxx (2013) xxx–xxxstudied 2000 women subjected to careHPV™ analysis and found a pos-
itive hr-HPV reaction in up to 12% of them. The important point to em-
phasize is that thesewomen live mostly in rural areas of São Paulo state
and other states of the Brazilian federation,where regularmedical assis-
tance and medical facilities are scarce. However, the fraction of women
we studied may not properly represent the rural population of São
Paulo State. We therefore sought to test a simple and reliable HPV test
in self- and non-self-collected samples to verify its potential use in
rural remote areas and low-resource settings of Brazil.
Considering the socio-demographic ﬁndings, no association was
found between hr-HPV positivity and tobacco use in either arm of the
analysis (molecular results or collection group). Concerning parity, sex-
ual partners and contraceptive use, no association with collection group
was found. These data could be used to illustrate an adequate andhomo-
geneous randomization system.However, these variables showed an as-
sociation with hr-HPV positivity, as illustrated in Table 1. With these
data, we hypothesize that our situation involves younger women,
most of whom are contraceptive users and have fewer children. In
other words, newer social and professional behaviors could increase
the rates of hr-HPV infection in this population.
The performance of the careHPV™ test has also been evaluated in
a large study conducted in China. Its accuracy was similar to that of
another molecular test (Hybrid Capture II, Qiagen)[9]. The careHPV
™ test had a higher sensitivity but a lower speciﬁcity compared
with liquid-based cytology and visual inspection with acetic acid
(VIA) to detect CIN2+, as described in the Chinese study. This
lower speciﬁcity of the careHPV™ test can be explained by the fact
that the presence of hr-HPV is not necessarily associated with a
high-grade lesion [10]. However, in our study, only one HSIL cytolog-
ical case was not found to be hr-HPV-positive using the molecular
test. Conversely, 26 of 33 LSIL cytology (78.8%) cases were found to
be hr-HPV positive using the molecular test. This end point raises
an important question regarding careHPV™ sensitivity, which differs
from that observed in other studies [9].
The careHPV™ test is expected to be commercially available in devel-
oping countries in the future. The results of HPV screening for cervical
cancer combined with those of the Chinese study of the new hr-HPV
test indicate that HPV testing is appropriate as a primary screening ap-
proach in low-resource settings for women who are at least 30 years of
age [9,18]. Moreover, several lines of evidence have conﬁrmed that
HPV testing is superior to cytology as a primary technical method for
screening.
In conclusion, the results presented herein demonstrate that self-
collection of vaginal samples is equivalent to cervical sampling for
HPV DNA detection and can be used in primary cervical cancer
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